Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METIMMOX-2 in Metastatic pMMR/MSS Colorectal Cancer
NCT05504252Phase 2Active, not recruiting
- Start
- Oct 2022
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal cancer (CRC). Primary endpoint: Progression-Free Survival up to 60 months. Started Oct 2022; status: active, not recruiting.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05504252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05504252.